Stefania Di Marco

Stefania Di Marco
Main position/role:
Scientific Director and Qualified Person, Advent S.r.l. (part of the IRBM group)
Stefania has been working for the past 12 years in clinical research and in good manufacturing practices of adenovirus-based vaccines for Infectious Diseases (HCV, malaria, RSV, HIV, Ebola, leishmaniasis, rabies, HBV, RVF and SARS-CoV-2).  She has 57 publications and four patents and 12-year experience in the evaluation of EU-funded research programmes (FP7, H2020, HORIZON, Eureka-Eurostars). Stefania worked for 18 years in preclinical drug discovery, employing molecular biology, biochemistry and X-ray crystallography (Novartis, Basel and IRBM-Merck, Pomezia).
She graduated in Biological Sciences in 1989, from the University of Rome La Sapienza and obtained a PhD in Cellular and Molecular Biology in 1994, from the University of Rome Tor Vergata.
Author: Admin